| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/02/2023 | 11.71% | B of A Securities | → $7.25 | Downgrades | Buy → Neutral |
| 10/16/2023 | 54.08% | Raymond James | $9 → $10 | Upgrades | Outperform → Strong Buy |
| 10/12/2023 | 38.67% | Stephens & Co. | → $9 | Initiates Coverage On | → Equal-Weight |
| 08/30/2023 | 84.9% | Morgan Stanley | $19 → $12 | Maintains | Overweight |
| 07/14/2023 | 192.76% | Morgan Stanley | $19 → $19 | Reiterates | Overweight → Overweight |
| 07/13/2023 | -7.55% | UBS | $8 → $6 | Maintains | Neutral |
| 07/07/2023 | 54.08% | JP Morgan | $12 → $10 | Maintains | Neutral |
| 05/01/2023 | 38.67% | Raymond James | → $9 | Upgrades | Market Perform → Outperform |
| 04/19/2023 | 84.9% | Goldman Sachs | $14 → $12 | Maintains | Buy |
| 03/03/2023 | 115.72% | Goldman Sachs | $21 → $14 | Maintains | Buy |
| 03/03/2023 | 84.9% | Piper Sandler | $19 → $12 | Maintains | Overweight |
| 03/02/2023 | 54.08% | TD Cowen | $17 → $10 | Maintains | Outperform |
| 02/23/2023 | 84.9% | JP Morgan | $22 → $12 | Downgrades | Overweight → Neutral |
| 11/21/2022 | — | Raymond James | Downgrades | Outperform → Market Perform | |
| 08/22/2022 | 161.94% | Cowen & Co. | $12 → $17 | Maintains | Outperform |
| 08/10/2022 | 192.76% | Morgan Stanley | $18 → $19 | Maintains | Overweight |
| 08/08/2022 | 161.94% | UBS | $11 → $17 | Maintains | Neutral |
| 08/08/2022 | 223.57% | Goldman Sachs | $14 → $21 | Maintains | Buy |
| 08/08/2022 | 223.57% | Barclays | $14 → $21 | Maintains | Overweight |
| 08/08/2022 | 238.98% | Raymond James | $20 → $22 | Maintains | Outperform |
| 08/05/2022 | 208.17% | Piper Sandler | $15 → $20 | Maintains | Overweight |
| 06/07/2022 | 177.35% | Morgan Stanley | $21 → $18 | Maintains | Overweight |
| 05/26/2022 | 115.72% | B of A Securities | $18 → $14 | Upgrades | Neutral → Buy |
| 05/12/2022 | 115.72% | Goldman Sachs | $16 → $14 | Maintains | Buy |
| 04/04/2022 | 192.76% | SVB Leerink | → $19 | Initiates Coverage On | → Outperform |
| 03/07/2022 | 146.53% | Goldman Sachs | $18 → $16 | Maintains | Buy |
| 03/07/2022 | 223.57% | Morgan Stanley | $25 → $21 | Maintains | Overweight |
| 03/04/2022 | 69.49% | Cowen & Co. | $24 → $11 | Maintains | Outperform |
| 02/24/2022 | 131.12% | Piper Sandler | $25 → $15 | Maintains | Overweight |
| 01/12/2022 | 208.17% | Raymond James | $30 → $20 | Maintains | Outperform |
| 12/14/2021 | 208.17% | Goldman Sachs | → $20 | Initiates Coverage On | → Buy |
| 12/03/2021 | 208.17% | JP Morgan | → $20 | Initiates Coverage On | → Overweight |
| 11/08/2021 | 331.43% | Barclays | $26 → $28 | Maintains | Overweight |
| 09/10/2021 | 269.8% | Cowen & Co. | → $24 | Initiates Coverage On | → Outperform |
| 08/31/2021 | 285.21% | Morgan Stanley | $38 → $25 | Maintains | Overweight |
| 08/12/2021 | 362.25% | Raymond James | $36 → $30 | Maintains | Outperform |
| 08/12/2021 | 285.21% | Barclays | → $25 | Initiates Coverage On | → Overweight |
| 07/02/2021 | 485.52% | Morgan Stanley | $36 → $38 | Maintains | Overweight |
| 05/18/2021 | 454.7% | Raymond James | $30 → $36 | Maintains | Outperform |
| 04/20/2021 | 454.7% | Morgan Stanley | → $36 | Initiates Coverage On | → Overweight |
| 04/20/2021 | 362.25% | Raymond James | → $30 | Initiates Coverage On | → Outperform |
| 04/20/2021 | 346.84% | B of A Securities | → $29 | Initiates Coverage On | → Neutral |
| 04/20/2021 | 331.43% | UBS | → $28 | Initiates Coverage On | → Neutral |
| 04/20/2021 | — | William Blair | Initiates Coverage On | → Outperform | |
| 04/20/2021 | 285.21% | Goldman Sachs | → $25 | Initiates Coverage On | → Neutral |
| 04/20/2021 | 362.25% | Piper Sandler | → $30 | Initiates Coverage On | → Overweight |
What is the target price for Alignment Healthcare (ALHC)?
The latest price target for Alignment Healthcare (NASDAQ: ALHC) was reported by B of A Securities on November 2, 2023. The analyst firm set a price target for $7.25 expecting ALHC to rise to within 12 months (a possible 11.71% upside). 14 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Alignment Healthcare (ALHC)?
The latest analyst rating for Alignment Healthcare (NASDAQ: ALHC) was provided by B of A Securities, and Alignment Healthcare downgraded their neutral rating.
When is the next analyst rating going to be posted or updated for Alignment Healthcare (ALHC)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Alignment Healthcare, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Alignment Healthcare was filed on November 2, 2023 so you should expect the next rating to be made available sometime around November 2, 2024.
Is the Analyst Rating Alignment Healthcare (ALHC) correct?
While ratings are subjective and will change, the latest Alignment Healthcare (ALHC) rating was a downgraded with a price target of $0.00 to $7.25. The current price Alignment Healthcare (ALHC) is trading at is $6.49, which is within the analyst's predicted range.